Anacor Pharmaceuticals Company Profile (NASDAQ:ANAC)

About Anacor Pharmaceuticals

Anacor Pharmaceuticals logoAnacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ANAC
  • CUSIP: 03242010
Key Metrics:
  • Previous Close: $99.20
  • 50 Day Moving Average: $93.23
  • 200 Day Moving Average: $81.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -162.62
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Anacor Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Anacor Pharmaceuticals (NASDAQ:ANAC) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $101.17 (1.98% upside)

Analysts' Ratings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateFirmActionRatingPrice TargetDetails
5/18/2016MizuhoDowngradeBuy -> Neutral$98.00 -> $99.25View Rating Details
5/16/2016Jefferies GroupReiterated RatingBuyView Rating Details
5/16/2016WedbushDowngradeOutperform -> Neutral$148.00 -> $99.25View Rating Details
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/9/2015JMP SecuritiesInitiated CoverageOutperform$173.00View Rating Details
7/21/2015Bank of America Corp.UpgradeNeutral -> BuyView Rating Details
7/21/2015Goldman Sachs Group Inc.UpgradeNeutral -> Buy$195.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.35)($0.36)$19.53 million$17.54 millionViewListenView Earnings Details
2/29/2016Q415($0.30)($0.43)$27.93 million$21.20 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.37)$25.60 million$24.60 millionViewListenView Earnings Details
8/6/2015Q215($0.32)($0.30)$18.55 million$21.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.49)($0.30)$9.20 million$15.26 millionViewN/AView Earnings Details
3/12/2015Q414($0.61)($0.24)$4.74 million$9.60 millionViewN/AView Earnings Details
11/6/2014Q314($0.66)($0.74)$3.67 million$3.96 millionViewN/AView Earnings Details
8/7/2014Q214($0.63)($0.58)$3.03 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.39)($0.51)$2.82 million$4.15 millionViewN/AView Earnings Details
3/13/2014Q413($0.39)$3.01$2.85 million$8.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.39)($0.41)$2.57 million$3.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.39)($0.36)$2.60 million$3.40 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.42)$2.57 million$1.71 billionViewN/AView Earnings Details
3/14/2013Q4 2012($0.45)($0.36)$3.25 million$3.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.45)($0.46)$3.18 million$2.47 millionViewN/AView Earnings Details
8/9/2012($0.45)($0.47)ViewN/AView Earnings Details
5/10/2012($0.44)($0.48)ViewN/AView Earnings Details
3/13/2012($0.35)($0.52)ViewN/AView Earnings Details
11/10/2011($0.41)($0.16)ViewN/AView Earnings Details
8/11/2011($0.45)($0.54)ViewN/AView Earnings Details
5/5/2011($0.31)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anacor Pharmaceuticals (NASDAQ:ANAC)
Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.45)($0.30)($0.38)
Q2 20162($0.41)($0.36)($0.39)
Q3 20162($0.44)($0.33)($0.39)
Q4 20162($0.74)($0.53)($0.64)
Q1 20171($0.53)($0.53)($0.53)
Q2 20171$0.52$0.52$0.52
Q3 20171$1.32$1.32$1.32
Q4 20171$1.67$1.67$1.67
(Data provided by Zacks Investment Research)


Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Graeme BellCFOSell751$99.28$74,559.28View SEC Filing  
5/23/2016Keith R LeonardDirectorSell9,000$99.70$897,300.00View SEC Filing  
5/16/2016Anders D HoveDirectorSell353,881$99.59$35,243,008.79View SEC Filing  
4/29/2016Ryan T SullivanEVPSell3,125$66.33$207,281.25View SEC Filing  
4/8/2016Anders D HoveDirectorSell229,301$71.10$16,303,301.10View SEC Filing  
3/22/2016Paul L BernsCEOSell37,500$60.31$2,261,625.00View SEC Filing  
1/19/2016Vincent P. IppolitoEVPSell20,000$95.41$1,908,200.00View SEC Filing  
1/15/2016Lee ZaneSVPSell1,466$89.57$131,309.62View SEC Filing  
1/4/2016Paul L. BernsCEOSell2,533$112.35$284,582.55View SEC Filing  
1/4/2016Ryan T. SullivanVPSell733$111.78$81,934.74View SEC Filing  
1/4/2016Vincent P. IppolitoEVPSell855$112.28$95,999.40View SEC Filing  
12/11/2015Paul L. BernsCEOSell20,000$117.26$2,345,200.00View SEC Filing  
12/10/2015Ryan T. SullivanVPSell10,000$110.41$1,104,100.00View SEC Filing  
9/15/2015Lee ZaneSVPSell14,000$139.84$1,957,760.00View SEC Filing  
9/15/2015Paul L. BernsCEOSell20,000$139.83$2,796,600.00View SEC Filing  
8/13/2015Paul L BernsCEOSell20,000$138.69$2,773,800.00View SEC Filing  
6/15/2015Lee ZaneSVPSell12,000$69.05$828,600.00View SEC Filing  
5/15/2015Jacob J PlattnerVPSell8,920$63.73$568,471.60View SEC Filing  
5/14/2015Carmen R RodriguezVPSell61,942$62.73$3,885,621.66View SEC Filing  
4/29/2015Ryan T SullivanVPSell3,125$53.61$167,531.25View SEC Filing  
4/27/2015Paul L BernsCEOSell50,000$63.64$3,182,000.00View SEC Filing  
4/15/2015Jacob J PlattnerVPSell8,920$62.81$560,265.20View SEC Filing  
3/23/2015Geoffrey M ParkerCFOBuy3,000$52.43$157,290.00View SEC Filing  
3/16/2015Jacob J PlattnerVPSell8,920$55.60$495,952.00View SEC Filing  
3/16/2015Lee ZaneSVPSell12,000$56.44$677,280.00View SEC Filing  
3/4/2015Sanjay ChandaSVPSell5,000$45.00$225,000.00View SEC Filing  
3/3/2015Vincent P IppolitoEVPSell9,000$43.88$394,920.00View SEC Filing  
3/2/2015Jacob J PlattnerVPSell6,875$44.02$302,637.50View SEC Filing  
3/2/2015Kirk R MaplesSVPSell600$43.95$26,370.00View SEC Filing  
1/2/2015Jacob J PlattnerVPSell6,875$32.09$220,618.75View SEC Filing  
12/26/2014Paul L BernsCEOSell25,000$30.82$770,500.00View SEC Filing  
12/12/2014Lucy ShapiroDirectorSell289,685$35.11$10,170,840.35View SEC Filing  
12/11/2014Lee ZaneSVPSell4,900$36.09$176,841.00View SEC Filing  
12/9/2014Kirk R MaplesSVPSell60,000$36.52$2,191,200.00View SEC Filing  
12/1/2014Jacob J PlattnerVPSell6,875$33.34$229,212.50View SEC Filing  
12/1/2014Kirk R MaplesSVPSell600$33.38$20,028.00View SEC Filing  
11/26/2014Sanjay ChandaSVPSell5,000$35.00$175,000.00View SEC Filing  
11/3/2014Jacob J PlattnerVPSell6,875$29.32$201,575.00View SEC Filing  
10/1/2014Jacob J PlattnerVPSell6,875$24.47$168,231.25View SEC Filing  
9/26/2014Anders D HoveDirectorSell20,000$25.00$500,000.00View SEC Filing  
9/19/2014Anders D HoveDirectorSell740,000$24.87$18,403,800.00View SEC Filing  
9/16/2014Anders D HoveDirectorSell90,000$24.99$2,249,100.00View SEC Filing  
9/10/2014Sanjay ChandaSVPSell10,000$24.25$242,500.00View SEC Filing  
9/8/2014Geoffrey M ParkerCFOBuy6,590$21.82$143,793.80View SEC Filing  
8/27/2014Mark LeschlyDirectorSell13,067$22.50$294,007.50View SEC Filing  
5/20/2014Kirk MaplesSVPSell1,500$14.15$21,225.00View SEC Filing  
4/21/2014Kirk MaplesSVPSell1,500$15.60$23,400.00View SEC Filing  
3/24/2014Geoffrey ParkerCFOBuy5,000$20.11$100,550.00View SEC Filing  
3/21/2014Lucy ShapiroDirectorSell80,000$21.14$1,691,200.00View SEC Filing  
3/20/2014Kirk MaplesSVPSell3,000$22.39$67,170.00View SEC Filing  
3/18/2014Geoffrey ParkerCFOBuy2,410$22.60$54,466.00View SEC Filing  
3/5/2014David PerryCEOSell65,000$20.22$1,314,300.00View SEC Filing  
2/20/2014Kirk MaplesSVPSell3,000$19.33$57,990.00View SEC Filing  
2/5/2014David PerryCEOSell15,000$17.00$255,000.00View SEC Filing  
1/21/2014Kirk MaplesSVPSell3,000$20.27$60,810.00View SEC Filing  
1/9/2014David PerryCEOSell65,000$16.32$1,060,800.00View SEC Filing  
12/9/2013David PerryCEOSell40,328$16.23$654,523.44View SEC Filing  
11/26/2013Geoffrey ParkerCFOBuy10,000$13.40$134,000.00View SEC Filing  
11/25/2013Geoffrey ParkerCFOBuy10,000$12.85$128,500.00View SEC Filing  
8/14/2013Kirk MaplesSVPSell1,052$9.71$10,214.92View SEC Filing  
8/13/2013Geoffrey ParkerCFOBuy50,000$8.34$417,000.00View SEC Filing  
6/19/2013Geoffrey M ParkerCFOBuy23,046$5.20$119,839.20View SEC Filing  
6/18/2013Geoffrey M ParkerCFOBuy20,000$5.22$104,400.00View SEC Filing  
6/14/2013Kirk R MaplesSVPSell5,600$5.39$30,184.00View SEC Filing  
11/26/2012Kirk R MaplesSVPSell3,000$5.22$15,660.00View SEC Filing  
11/1/2012Kirk R MaplesSVPSell3,000$5.81$17,430.00View SEC Filing  
10/5/2012Lucy ShapiroDirectorSell30,000$6.67$200,100.00View SEC Filing  
8/22/2012Geoffrey M ParkerCFOBuy5,000$6.19$30,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Anacor Pharmaceuticals (NASDAQ:ANAC)
News IconAnacor Pharmaceuticals, Inc. (ANAC) Updated Broker Price Targets - The De Soto Edge (NASDAQ:ANAC) - October 20 at 9:20 AM logoAtopic Dermatitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast Upto 2019 (NASDAQ:ANAC) - October 19 at 8:21 AM logoGlobal Cancer Immunotherapy Drugs Market 2016-2022: Market is Expected to Reach $119.39 Billion by 2022 from $61.9 Billion in 2014 - Research and Markets (NASDAQ:ANAC) - October 19 at 8:21 AM logoGlobal Cancer Immunotherapy Drugs Market 2016-2022: Market is ... - Business Wire (press release) (NASDAQ:ANAC) - October 17 at 3:28 PM logoPfizer: What Will The Dividend Increase Be? (NASDAQ:ANAC) - October 14 at 12:00 PM logoPfizer Inc. (PFE): Safe And Steady Dividends - Insider Monkey (blog) (NASDAQ:ANAC) - October 12 at 8:49 PM logoThe Pfizer-Anacor Deal: A Review (NASDAQ:ANAC) - October 10 at 3:28 PM
News IconBroker Roundup For Anacor Pharmaceuticals, Inc. (ANAC) - The De Soto Edge (NASDAQ:ANAC) - October 3 at 8:15 AM
News IconDermatophytic Onychomycosis Therapeutics Market Opportunities & Investment Research Report 2020 (NASDAQ:ANAC) - September 30 at 3:58 PM
News IconDrugmaker Pfizer decides not to break up business - The Daily Telegram (NASDAQ:ANAC) - September 27 at 3:29 PM
News IconPfizer, which has big NC presence, decides not to split (NASDAQ:ANAC) - September 26 at 8:30 PM
News IconPfizer, maker of Viagra, will not split into two companies (NASDAQ:ANAC) - September 26 at 8:30 PM logoRead Scraps Pfizer Break-up As Megadeals Escape Its Grasp - (NASDAQ:ANAC) - September 26 at 3:29 PM
News IconAllergan to buy three companies for combined $2.4 billion (NASDAQ:ANAC) - September 24 at 8:48 AM logoDermata Therapeutics, LLC Announced the Addition of Wendell ... - PR Newswire (press release) (NASDAQ:ANAC) - September 21 at 4:25 PM
News IconAnacor Pharmaceuticals Inc (ANAC) CFO Graeme Bell Sells 751 Shares - DailyQuint (NASDAQ:ANAC) - September 21 at 4:25 PM
News IconAnacor Pharmaceuticals, Inc. Pipeline Review, Industry Analysis, Size and Clinical trial 2016 - 2020 - Medgadget (blog) (NASDAQ:ANAC) - September 21 at 4:25 PM
News IconDermatology Grand Rounds (NASDAQ:ANAC) - September 21 at 9:22 AM logoDermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors (NASDAQ:ANAC) - September 20 at 9:23 AM
News IconWeekly Research Analysts' Ratings Updates for Anacor Pharmaceuticals (ANAC) - DailyQuint (NASDAQ:ANAC) - September 17 at 3:31 PM
News IconWhat To Keep In Mind As Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Goes To Allergan - Scibility Media (NASDAQ:ANAC) - September 16 at 3:28 PM logoBetter Buy: Pfizer Inc. vs. AbbVie Inc. - Motley Fool (NASDAQ:ANAC) - September 15 at 3:29 PM logoAllergan to Buy Vitae Pharmaceuticals for $639 Million - Wall Street Journal (NASDAQ:ANAC) - September 14 at 3:29 PM
News IconBrokers Update Target Prices On Anacor Pharmaceuticals, Inc. (ANAC) - National Daily Press (NASDAQ:ANAC) - September 13 at 8:19 AM logoGilead Sciencs, Inc. a Takeover Target? It's Not as Crazy As It Sounds - Motley Fool (NASDAQ:ANAC) - September 12 at 8:19 AM
News IconMondelez and Reynolds Boast Fat Profit Margins - Virginian-Pilot (NASDAQ:ANAC) - September 10 at 3:28 PM logoGlobal Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account … (NASDAQ:ANAC) - September 10 at 8:16 AM
News IconAnacor Pharmaceuticals, Inc. (NASDAQ:ANAC): What is the Sell-side Making of this Stock? - Post News (NASDAQ:ANAC) - September 9 at 8:17 AM
News IconPlacing Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Shares Under the Microscope - National Daily Press (NASDAQ:ANAC) - September 9 at 8:17 AM
News IconOn Investments: Profit margins can offer hint that a stock is strong - Omaha World-Herald (NASDAQ:ANAC) - September 7 at 12:27 PM
News IconDorfman: Fat profit margins can be sign of great stock - Tribune-Review (NASDAQ:ANAC) - September 6 at 8:16 AM logoSeizures Pipeline H2 2016 Market Review Research Report - MarketWatch (NASDAQ:ANAC) - September 2 at 8:10 AM logoSeizures Pipeline H2 2016 Market Review Research Report - Yahoo Finance (NASDAQ:ANAC) - September 1 at 3:31 PM logoWhat Investors Should Know about the Pfizer-Anacor Deal (NASDAQ:ANAC) - August 29 at 4:08 PM
News IconGame On for Pfizer With $14 Billion Medivation Buyout (or, Why ... - (NASDAQ:ANAC) - August 27 at 3:29 PM logoPfizer-Anacor Deal Completed in June 2016 (NASDAQ:ANAC) - August 26 at 11:39 AM logoWhy Pfizer's Acquisition of Anacor Is a Great Fit (NASDAQ:ANAC) - August 26 at 11:39 AM
News IconPfizer deal highlights US Pharma trend for targeted M&A: Fitch (NASDAQ:ANAC) - August 25 at 8:17 AM
News IconPfizer makes 2nd acquisition in week with AstraZeneca deal (NASDAQ:ANAC) - August 25 at 8:17 AM
News IconPfizer to buy US cancer drug company for $14 billion (NASDAQ:ANAC) - August 24 at 11:47 AM logoWrite A Prescription For More Pharma M&A With This ETF (NASDAQ:ANAC) - August 24 at 11:47 AM
News IconPfizer Makes Cancer Play With Medivation Deal (NASDAQ:ANAC) - August 23 at 7:46 AM
News IconPfizer buys Medivation for $14 bn to boost cancer drug roster (NASDAQ:ANAC) - August 23 at 7:46 AM
News IconPfizer to buy Medivation in $14-billion deal (NASDAQ:ANAC) - August 23 at 7:46 AM logoPfizer boosts cancer drug roster with $14B Medivation deal (NASDAQ:ANAC) - August 23 at 7:46 AM
News IconCan the Crowd & Analysts Agree on Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)? - Post News (NASDAQ:ANAC) - August 21 at 8:15 AM logoWhy Pfizer's Acquisition of Anacor Is a Great Fit -- The Motley Fool - Motley Fool (NASDAQ:ANAC) - August 20 at 8:31 AM logoActivist Keith Meister Unloads Large Pfizer (PFE) Position, Takes Stakes in B/E Aerospace (BEAV), Johnson Controls ... - Insider Monkey (blog) (NASDAQ:ANAC) - August 18 at 3:37 PM
News IconWhy Pfizer's Acquisition of Anacor Is a Great Fit - (NASDAQ:ANAC) - August 18 at 3:37 PM logoBay Area M&A activity drives new startup growth (NASDAQ:ANAC) - August 12 at 12:05 PM


Anacor Pharmaceuticals (NASDAQ:ANAC) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff